<?xml version="1.0" encoding="UTF-8"?>
<ref id="B8">
 <mixed-citation publication-type="book">
  <person-group person-group-type="author">
   <name>
    <surname>Bellingan</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Jacono</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Bannard-Smith</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Brealey</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Meyer</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Thickett</surname>
    <given-names>D.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2019</year>). 
  <source>Primary Analysis of a Phase 1/2 Study to Assess MultiStem® Cell Therapy, a Regenerative Advanced Therapy Medicinal Product (ATMP), in Acute Respiratory Distress Syndrome (MUST-ARDS). In: B14 LATE BREAKING CLINICAL TRIALS</source> (
  <publisher-name>American Thoracic Society</publisher-name>), 
  <fpage>A7353</fpage>–
  <lpage>A7353</lpage>. 
  <pub-id pub-id-type="doi">10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A7353</pub-id>
 </mixed-citation>
</ref>
